Forbius, a clinical-stage protein engineering company that develops biotherapeutics to treat fibrosis and cancer, has completed enrollment in the Phase 1a solid tumour trial exploring the safety and tolerability of AVID200, a first-in-class TGF-beta 1 & 3 selective inhibitor, administered as a monotherapy, it was reported yesterday.
The product is rationally designed to selectively and potently inhibit the main pathogenic TGF-beta isoforms 1 and 3. It spares TGF-beta 2 for optimal safety.
The AVID200-03 trial (NCT03834662) is an open label, multicentre, dose-escalation study concentrated on showcasing the safety of AVID200 monotherapy in patients with advanced or metastatic solid tumour malignancies and no other treatment options. Following a standard 3 + 3 design, a total of 15 patients received AVID200 at 5, 15 and 30mg/kg once every three weeks. Pharmacokinetics and target engagement were also assessed.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval